文献速递临床试验与 GCP

玻璃体切除术、视网膜下组织型纤溶酶原激活剂及玻璃体腔注气治疗渗出性年龄相关性黄斑变性继发黄斑下出血(TIGER):研究方案更新及统计分析计划与卫生经济学分析计划的补充

Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial.
PubMed 文献 · Trials · 2025-04-14

TIGER试验是一项泛欧洲、两组、非商业性、活性对照、观察者设盲、优效性、随机对照外科临床试验,研究玻璃体切除术联合视网膜下组织型纤溶酶原激活剂及玻璃体腔注气治疗渗出性年龄相关性黄斑变性继发的黄斑下出血。本文报告研究方案2.0版(2022年1月18日起获批)和3.0版(2023年4月25日起获批)的关键变更,并纳入当前版本的统计分析计划和卫生经济学分析计划。主要分析为第12个月访视时研究眼ETDRS字母数增加≥10个的参与者比例组间差异,主要卫生经济学分析为12个月时组间质量调整生命年差异。

要点

  • TIGER试验为泛欧洲随机对照外科临床试验,评估玻璃体切除术联合视网膜下tPA及玻璃体腔注气治疗黄斑下出血。
  • 方案更新涉及三项入选排除标准、次要结局及允许的研究用药品变更。
  • 主要分析为第12个月研究眼ETDRS字母数增加≥10个的参与者比例组间差异。

核心结论

  • 本文报告TIGER试验方案2.0版和3.0版的关键变更,并纳入当前版本的统计分析计划和卫生经济学分析计划。

研究设计与样本

  • TIGER试验为泛欧洲、两组、非商业性、活性对照、观察者设盲、优效性、随机对照外科临床试验,研究用药品为研究性药品。
  • 原始方案于2022年1月31日发表,本更新报告2.0版(自2022年1月18日起获批用于试验中心)和3.0版(自2023年4月25日起获批用于试验中心)的关键变更。
  • 试验注册号:ClinicalTrials.gov NCT04663750;EudraCT 2020-004917-10。

主要发现

  • 排除标准2中删除「Actilyse」一词。
  • 排除标准5更新为:末次阿柏西普暴露后最多12周内必须禁欲异性性交或使用高效避孕方法。
  • 排除标准6澄清:关于国际标准化比值(INR)仅适用于接受华法林治疗的参与者。
  • 次要结局变更:Radner阅读速度仅限研究眼;EQ-5D-5L从次要报告的疗效结局改为仅作为卫生经济学分析组成部分报告。
  • Actilyse Cathflo作为额外允许的研究用药品加入,因英国实践中已使用且与Actilyse 10 mg分子相同。

关键数值与推荐

  • 主要分析为第12个月访视时研究眼ETDRS字母数增加≥10个的参与者比例组间差异。
  • 主要卫生经济学分析为12个月时组间质量调整生命年差异。
  • 研究方案允许抗VEGF治疗间最短窗口为21天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER) trial is a pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical clinical trial of an investigational medicinal product. METHODS: The original protocol for this trial was published on 31 January 2022 ( https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05966-3 ). This update reports on key changes in the study protocol in version 2.0 which was approved for trial sites from 18 January 2022, and the current version 3.0 which was approved for trial sites from 25 April 2023, and includes current versions of the statistical analysis plan and health economics analysis plan. In summary, there have been changes to three eligibility criteria: removing the word "Actilyse" from exclusion criterion 2, updating exclusion criterion 5 to state abstinence from heterosexual intercourse or the use of highly effective methods of birth control is mandatory for up to 12 weeks after last aflibercept exposure on trial, and clarifying exclusion criterion 6 relating to international normalised ratio (INR) is only applicable to participants receiving warfarin. Changes to secondary outcomes include Radner Reading speed being limited to the study eye only, and moving EQ-5D-5L from a secondary reported efficacy outcome to a component of health economic analysis reporting only. Actilyse Cathflo was added as an additional permitted investigational medicinal product as this is already used in practice in the UK and is molecularly identical to Actilyse 10 mg. Instructions were added to account for participants who had already been exposed to aflibercept or a similar anti-vascular endothelial growth factor (anti-VEGF) within 21 days (the minimum window between anti-VEGF treatments permitted on trial) prior to study enrolment, storage of tissue plasminogen activator in theatre and operating room environments, and the recording of additional, as-needed aflibercept treatments in-between study visits at the discretion of the study investigator. Finally, sections and subsections have been added to detail the imaging analysis plan, patient public involvement plan, INR testing, and recruitment and informed consent components of the trial. The primary analysis of the trial as stated in the statistical analysis plan is the difference between groups in the proportion of participants gaining ≥ 10 ETDRS letters in their study eye at the month 12 visit, whilst the primary health economic analysis of the trial is the difference in quality-adjusted life years between groups at 12 months. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04663750 ; EudraCT: 2020-004917-10.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee CN, Desai R, Ramazzotto L, et al. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial. Trials. 2025. PMID: 40229856. doi:10.1186/s13063-025-08727-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。